- Home
- SGML vs MNMD Comparison
SGML vs MNMD Comparison
Compare SGML & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGML
- MNMD
- Stock Information
- Founded
- SGML 2011
- MNMD 2019
- Country
- SGML Brazil
- MNMD United States
- Employees
- SGML N/A
- MNMD N/A
- Industry
- SGML Industrial Machinery/Components
- MNMD Pharmaceuticals and Biotechnology
- Sector
- SGML Industrials
- MNMD Health Care
- Exchange
- SGML Nasdaq
- MNMD Nasdaq
- Market Cap
- SGML 743.4M
- MNMD 811.9M
- IPO Year
- SGML N/A
- MNMD N/A
- Fundamental
- Price
- SGML $6.41
- MNMD $12.58
- Analyst Decision
- SGML Strong Buy
- MNMD Strong Buy
- Analyst Count
- SGML 1
- MNMD 7
- Target Price
- SGML $16.00
- MNMD $26.71
- AVG Volume (30 Days)
- SGML 3.2M
- MNMD 1.9M
- Earning Date
- SGML 11-14-2025
- MNMD 11-06-2025
- Dividend Yield
- SGML N/A
- MNMD N/A
- EPS Growth
- SGML N/A
- MNMD N/A
- EPS
- SGML N/A
- MNMD N/A
- Revenue
- SGML $134,494,014.00
- MNMD N/A
- Revenue This Year
- SGML $40.75
- MNMD N/A
- Revenue Next Year
- SGML $63.82
- MNMD N/A
- P/E Ratio
- SGML N/A
- MNMD N/A
- Revenue Growth
- SGML N/A
- MNMD N/A
- 52 Week Low
- SGML $4.25
- MNMD $4.70
- 52 Week High
- SGML $15.56
- MNMD $12.94
- Technical
- Relative Strength Index (RSI)
- SGML 47.63
- MNMD 63.95
- Support Level
- SGML $6.90
- MNMD $11.68
- Resistance Level
- SGML $7.99
- MNMD $12.94
- Average True Range (ATR)
- SGML 0.68
- MNMD 0.86
- MACD
- SGML -0.06
- MNMD 0.06
- Stochastic Oscillator
- SGML 17.24
- MNMD 84.83
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).